Chemokine-chemokine receptors in cancer immunotherapy (Q37773282)

22 August 2017

1 reference

title

Chemokine-chemokine receptors in cancer immunotherapy (English)

1 reference

22 August 2017

1 reference

Mark J Smyth

2

0 references

author name string

Trina J Stewart

series ordinal

1

1 reference

22 August 2017

publication date

1 January 2009

1 reference

22 August 2017

1 reference

22 August 2017

volume

1

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

109-127

1 reference

Chemokines: multiple levels of leukocyte migration control.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Dendritic cell biology and regulation of dendritic cell trafficking by chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Chemokines and dendritic cells: a crucial alliance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Chemokines: agents for the immunotherapy of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CCR5 expression influences the progression of human breast cancer in a p53-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Molecular investigation of the stromal cell-derived factor-1 chemokine in lymphoid leukemia and lymphoma patients from Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Intrinsic tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Chemokine signaling via the CXCR2 receptor reinforces senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Involvement of chemokine receptors in breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The significance of cancer cell expression of the chemokine receptor CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

A multigenic program mediating breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Molecular characterization of the tumor microenvironment in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Roots and stems: stem cells in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Neutrophil chemorepulsion in defined interleukin-8 gradients in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Role of tumor-associated macrophages in tumor progression and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Regulatory T cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Immunological responses can have both pro- and antitumour effects: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CCR4 as a novel molecular target for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The terminology issue for myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Derangement of immune responses by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The macrophage growth factor CSF-1 in mammary gland development and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Heparin-disaccharide affects T cells: inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Activation of human macrophages by allogeneic islets preparations: inhibition by AOP-RANTES and heparinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Discovery of small molecule CXCR4 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Manipulating the chemokine-chemokine receptor network to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Gene modification strategies to induce tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Interleukin-12: biological properties and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

CXCL12-3′A Polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.109

21 January 2018

Identifiers

DOI

10.2217/1750743X.1.1.109

1 reference

22 August 2017

1 reference